Fexofenadine is a metabolite of terfenadine and is a second-generation antihistamine. It is FDA approved to treat seasonal allergic rhinitis and chronic idiopathic urticaria. Fexofenadine is a medication used to manage and treat allergic rhinitis and chronic urticaria. Fexofenadine has approval for use in both children and adults. Children should be six months old or older, dependent upon the indication for use. This activity outlines the indications, action, and contraindications for fexofenadine as a valuable agent in treating allergic rhinitis and chronic urticaria. In addition, this activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions) pertinent to members of the interprofessional team in the treatment of patients with seasonal allergic rhinitis and related conditions.

**Objectives:**
- Identify the mechanism of action of fexofenadine.
- Describe the adverse effects of fexofenadine.
- Review the appropriate monitoring for the toxicity of fexofenadine.
- Summarize interprofessional team strategies for improving care coordination and communication to advance fexofenadine and improve outcomes.